CR20190106A - Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres - Google Patents
Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceresInfo
- Publication number
- CR20190106A CR20190106A CR20190106A CR20190106A CR20190106A CR 20190106 A CR20190106 A CR 20190106A CR 20190106 A CR20190106 A CR 20190106A CR 20190106 A CR20190106 A CR 20190106A CR 20190106 A CR20190106 A CR 20190106A
- Authority
- CR
- Costa Rica
- Prior art keywords
- autoimmune
- treatment
- inflammatory diseases
- cancers
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Compuestos de fórmula (I) y sales de los mismos (I) en la que R1, R2, R3 y a son como se definen en el presente documento. Se ha descubierto que los compuestos de fórmula (I) y sales de los mismos inhiben la unión de la familia BET de proteínas que contienen bromodominios a, por ejemplo, residuos de lisina acetilados y, por tanto, pueden tener uso en terapia, por ejemplo, en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide; y cánceresCompounds of formula (I) and salts thereof: Formula (I) wherein R1, R2, R3 and a are as defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1614934.6A GB201614934D0 (en) | 2016-09-02 | 2016-09-02 | Chemical compounds |
PCT/EP2017/071868 WO2018041947A1 (en) | 2016-09-02 | 2017-08-31 | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190106A true CR20190106A (es) | 2019-05-02 |
Family
ID=57140084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190106A CR20190106A (es) | 2016-09-02 | 2017-08-31 | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres |
Country Status (24)
Country | Link |
---|---|
US (1) | US20190175571A1 (es) |
EP (1) | EP3507283A1 (es) |
JP (1) | JP2019526577A (es) |
KR (1) | KR20190042701A (es) |
CN (1) | CN109790147A (es) |
AR (1) | AR109487A1 (es) |
AU (1) | AU2017317724A1 (es) |
BR (1) | BR112019004241A2 (es) |
CA (1) | CA3035312A1 (es) |
CL (1) | CL2019000538A1 (es) |
CO (1) | CO2019001871A2 (es) |
CR (1) | CR20190106A (es) |
DO (1) | DOP2019000047A (es) |
EA (1) | EA201990410A1 (es) |
GB (1) | GB201614934D0 (es) |
JO (1) | JOP20190029A1 (es) |
MA (1) | MA46085A (es) |
MX (1) | MX2019002491A (es) |
PE (1) | PE20190478A1 (es) |
PH (1) | PH12019500460A1 (es) |
SG (1) | SG11201901673SA (es) |
TW (1) | TW201817724A (es) |
UY (1) | UY37393A (es) |
WO (1) | WO2018041947A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20190101A (es) | 2016-09-02 | 2019-07-04 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
CN111686107B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途 |
CN111588725B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途 |
CN111588721B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途 |
CN111686114B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途 |
WO2024018423A1 (en) * | 2022-07-21 | 2024-01-25 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
CN117257964B (zh) * | 2023-10-25 | 2024-04-02 | 苏州大学 | 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3406329A1 (de) * | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
DE4034060A1 (de) * | 1990-10-26 | 1992-04-30 | Basf Ag | Biskationische azofarbstoffe |
DE19809994B4 (de) * | 1997-03-19 | 2006-02-09 | Basf Ag | Clathrate von Bis-[6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(phen-4-ylazo)-pyridin-2-on]ethylen |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
JP4388997B2 (ja) * | 2006-09-05 | 2009-12-24 | 協和発酵キリン株式会社 | イミダゾール誘導体 |
CN102015686B (zh) * | 2008-03-21 | 2014-07-02 | 诺华股份有限公司 | 杂环化合物及其用途 |
CA2726588C (en) * | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
CA2789474A1 (en) * | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
AU2013365926B9 (en) * | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
-
2016
- 2016-09-02 GB GBGB1614934.6A patent/GB201614934D0/en not_active Ceased
-
2017
- 2017-06-16 JO JOP/2019/0029A patent/JOP20190029A1/ar unknown
- 2017-08-31 AU AU2017317724A patent/AU2017317724A1/en not_active Abandoned
- 2017-08-31 JP JP2019511919A patent/JP2019526577A/ja active Pending
- 2017-08-31 WO PCT/EP2017/071868 patent/WO2018041947A1/en unknown
- 2017-08-31 KR KR1020197009266A patent/KR20190042701A/ko not_active Application Discontinuation
- 2017-08-31 EP EP17758878.7A patent/EP3507283A1/en not_active Withdrawn
- 2017-08-31 TW TW106129714A patent/TW201817724A/zh unknown
- 2017-08-31 MA MA046085A patent/MA46085A/fr unknown
- 2017-08-31 MX MX2019002491A patent/MX2019002491A/es unknown
- 2017-08-31 AR ARP170102425A patent/AR109487A1/es unknown
- 2017-08-31 US US16/326,991 patent/US20190175571A1/en not_active Abandoned
- 2017-08-31 CN CN201780059730.0A patent/CN109790147A/zh active Pending
- 2017-08-31 BR BR112019004241A patent/BR112019004241A2/pt not_active Application Discontinuation
- 2017-08-31 PE PE2019000455A patent/PE20190478A1/es unknown
- 2017-08-31 EA EA201990410A patent/EA201990410A1/ru unknown
- 2017-08-31 UY UY0001037393A patent/UY37393A/es not_active Application Discontinuation
- 2017-08-31 SG SG11201901673SA patent/SG11201901673SA/en unknown
- 2017-08-31 CA CA3035312A patent/CA3035312A1/en not_active Abandoned
- 2017-08-31 CR CR20190106A patent/CR20190106A/es unknown
-
2019
- 2019-02-27 CO CONC2019/0001871A patent/CO2019001871A2/es unknown
- 2019-02-28 CL CL2019000538A patent/CL2019000538A1/es unknown
- 2019-02-28 DO DO2019000047A patent/DOP2019000047A/es unknown
- 2019-03-01 PH PH12019500460A patent/PH12019500460A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201817724A (zh) | 2018-05-16 |
PH12019500460A1 (en) | 2019-12-16 |
WO2018041947A1 (en) | 2018-03-08 |
UY37393A (es) | 2018-03-23 |
JOP20190029A1 (ar) | 2019-02-25 |
JP2019526577A (ja) | 2019-09-19 |
EP3507283A1 (en) | 2019-07-10 |
PE20190478A1 (es) | 2019-04-04 |
US20190175571A1 (en) | 2019-06-13 |
CL2019000538A1 (es) | 2019-05-17 |
CO2019001871A2 (es) | 2019-03-08 |
CA3035312A1 (en) | 2018-03-08 |
EA201990410A1 (ru) | 2019-09-30 |
MX2019002491A (es) | 2019-07-08 |
SG11201901673SA (en) | 2019-03-28 |
DOP2019000047A (es) | 2019-03-15 |
GB201614934D0 (en) | 2016-10-19 |
CN109790147A (zh) | 2019-05-21 |
KR20190042701A (ko) | 2019-04-24 |
AR109487A1 (es) | 2018-12-12 |
BR112019004241A2 (pt) | 2019-06-04 |
MA46085A (fr) | 2019-07-10 |
AU2017317724A1 (en) | 2019-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2017000213A (es) | Derivados de bencimidazol como inhibidores de bromodominio | |
CR20190106A (es) | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres | |
CY1121850T1 (el) | Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων | |
CO2017011484A2 (es) | Inhibidores de bromodominio | |
CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
CO2021005987A2 (es) | Compuestos de anillo fusionado | |
CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
CA2999253C (en) | Heterocyclic compounds and uses thereof | |
CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
CR20160229A (es) | Inhibidires de bromodominio | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
UY34977A (es) | 2,3-benzodiazepinas | |
CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
SV2016005316A (es) | Compuestos y composiciones para inducir condrogénesis | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
PE20190778A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida |